{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:33:29Z","timestamp":1793738009944,"version":"4.6.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To assess the effectiveness and tolerability of brivaracetam (BRV) in adults with epilepsy by specific comorbidities and epilepsy etiologies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>EXPERIENCE\/EPD332 was a pooled analysis of individual patient records from several non-interventional studies of patients with epilepsy initiating BRV in clinical practice. Outcomes included\u2009\u2265\u200950% reduction from baseline in seizure frequency, seizure freedom (no seizures within prior 3\u00a0months), continuous seizure freedom (no seizures since baseline), BRV discontinuation, and treatment-emergent adverse events (TEAEs) at 3, 6, and 12\u00a0months. Analyses were performed for all adult patients (\u2265\u200916\u00a0years of age) and stratified by comorbidity and by etiology at baseline (patients with cognitive\/learning disability [CLD], psychiatric comorbidity, post-stroke epilepsy, brain tumor\u2212related epilepsy [BTRE], and traumatic brain injury\u2212related epilepsy [TBIE]).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>At 12\u00a0months,\u2009\u2265\u200950% seizure reduction was achieved in 35.6% (<jats:italic>n<\/jats:italic>\u2009=\u2009264), 38.7% (<jats:italic>n<\/jats:italic>\u2009=\u2009310), 41.7% (<jats:italic>n<\/jats:italic>\u2009=\u200924), 34.1% (<jats:italic>n<\/jats:italic>\u2009=\u200941), and 50.0% (<jats:italic>n<\/jats:italic>\u2009=\u200928) of patients with CLD, psychiatric comorbidity, post-stroke epilepsy, BTRE, and TBIE, respectively; and continuous seizure freedom was achieved in 5.7% (<jats:italic>n<\/jats:italic>\u2009=\u2009318), 13.7% (n\u2009=\u2009424), 29.4% (n\u2009=\u200934), 11.4% (<jats:italic>n<\/jats:italic>\u2009=\u200944), and 13.8% (<jats:italic>n<\/jats:italic>\u2009=\u200929), respectively. During the study follow-up, in patients with CLD, psychiatric comorbidity, post-stroke epilepsy, BTRE, and TBIE, 37.1% (<jats:italic>n<\/jats:italic>\u2009=\u2009403), 30.7% (<jats:italic>n<\/jats:italic>\u2009=\u2009605), 33.3% (<jats:italic>n<\/jats:italic>\u2009=\u200951), 39.7% (<jats:italic>n<\/jats:italic>\u2009=\u200968), and 27.1% (<jats:italic>n<\/jats:italic>\u2009=\u200949) of patients discontinued BRV, respectively; and TEAEs since prior visit at 12\u00a0months were reported in 11.3% (<jats:italic>n<\/jats:italic>\u2009=\u2009283), 10.0% (<jats:italic>n<\/jats:italic>\u2009=\u2009410), 16.7% (<jats:italic>n<\/jats:italic>\u2009=\u200936), 12.5% (<jats:italic>n<\/jats:italic>\u2009=\u200948), and 3.0% (<jats:italic>n<\/jats:italic>\u2009=\u200933), respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>BRV as prescribed in the real world is effective and well tolerated among patients with CLD, psychiatric comorbidity, post-stroke epilepsy, BTRE, and TBIE.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00415-024-12253-z","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T11:01:36Z","timestamp":1709550096000},"page":"3169-3185","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Effectiveness and tolerability of brivaracetam in patients with epilepsy stratified by comorbidities and etiology in the real world: 12-month subgroup data from the international EXPERIENCE pooled analysis"],"prefix":"10.1007","volume":"271","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5936-6627","authenticated-orcid":false,"given":"Jerzy P.","family":"Szaflarski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Besson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1750-5131","authenticated-orcid":false,"given":"Wendyl","family":"D\u2019Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Faught","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Reuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3989-7471","authenticated-orcid":false,"given":"Felix","family":"Rosenow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Salas-Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Soto Insuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5995-5862","authenticated-orcid":false,"given":"Bernhard J.","family":"Steinhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6288-9915","authenticated-orcid":false,"given":"Adam","family":"Strzelczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Bourikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florin","family":"Floricel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Friesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Laloyaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2080-8042","authenticated-orcid":false,"given":"Vicente","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,4]]},"reference":[{"key":"12253_CR1","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1056\/NEJM200002033420503","volume":"342","author":"P Kwan","year":"2000","unstructured":"Kwan P, Brodie MJ (2000) Early identification of refractory epilepsy. N Engl J Med 342:314\u2013319. https:\/\/doi.org\/10.1056\/NEJM200002033420503","journal-title":"N Engl J Med"},{"key":"12253_CR2","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1111\/epi.16610","volume":"61","author":"AA Asadi-Pooya","year":"2020","unstructured":"Asadi-Pooya AA, Beniczky S, Rubboli G, Sperling MR, Rampp S, Perucca E (2020) A pragmatic algorithm to select appropriate antiseizure medications in patients with epilepsy. Epilepsia 61:1668\u20131677. https:\/\/doi.org\/10.1111\/epi.16610","journal-title":"Epilepsia"},{"key":"12253_CR3","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1111\/epi.17017","volume":"62","author":"JI Doerrfuss","year":"2021","unstructured":"Doerrfuss JI, Kowski AB, Holtkamp M (2021) Etiology-specific response to antiseizure medication in focal epilepsy. Epilepsia 62:2133\u20132141. https:\/\/doi.org\/10.1111\/epi.17017","journal-title":"Epilepsia"},{"key":"12253_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.rmu.2016.11.003","volume":"19","author":"MC Dom\u00ednguez-Aguilera","year":"2017","unstructured":"Dom\u00ednguez-Aguilera MC, Mu\u00f1iz-Landeros CE (2017) Prevalence of psychiatric disorders in patients with epilepsy in a tertiary level care hospital: Detection through the MINI PLUS International Structured Interview. Medicina Universitaria 19:3\u20136. https:\/\/doi.org\/10.1016\/j.rmu.2016.11.003","journal-title":"Medicina Universitaria"},{"key":"12253_CR5","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3390\/jcm11010267","volume":"11","author":"A Novak","year":"2022","unstructured":"Novak A, Vizjak K, Rakusa M (2022) Cognitive Impairment in People with Epilepsy. J Clin Med 11:267\u00a0https:\/\/doi.org\/10.3390\/jcm11010267","journal-title":"J Clin Med"},{"key":"12253_CR6","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1212\/con.0000000000001123","volume":"28","author":"M Mula","year":"2022","unstructured":"Mula M, Coleman H, Wilson SJ (2022) Neuropsychiatric and Cognitive Comorbidities in Epilepsy. Continuum (Minneap Minn) 28:457\u2013482. https:\/\/doi.org\/10.1212\/con.0000000000001123","journal-title":"Continuum (Minneap Minn)"},{"key":"12253_CR7","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/1756285611417920","volume":"4","author":"CM Eddy","year":"2011","unstructured":"Eddy CM, Rickards HE, Cavanna AE (2011) The cognitive impact of antiepileptic drugs. Ther Adv Neurol Disord 4:385\u2013407. https:\/\/doi.org\/10.1177\/1756285611417920","journal-title":"Ther Adv Neurol Disord"},{"key":"12253_CR8","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.1212\/CPJ.0000000000000874","volume":"11","author":"M Mula","year":"2021","unstructured":"Mula M, Kanner AM, Jett\u00e9 N, Sander JW (2021) Psychiatric Comorbidities in People With Epilepsy. Neurol Clin Pract 11:e112\u2013e120. https:\/\/doi.org\/10.1212\/CPJ.0000000000000874","journal-title":"Neurol Clin Pract"},{"key":"12253_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1517\/14740338.3.1.1","volume":"3","author":"FMC Besag","year":"2004","unstructured":"Besag FMC (2004) Behavioural effects of the newer antiepileptic drugs: an update. Expert Opin Drug Saf 3:1\u20138. https:\/\/doi.org\/10.1517\/14740338.3.1.1","journal-title":"Expert Opin Drug Saf"},{"key":"12253_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/j.1528-1167.2006.00684.x","volume":"47","author":"B Schmitz","year":"2006","unstructured":"Schmitz B (2006) Effects of antiepileptic drugs on mood and behavior. Epilepsia 47:28\u201333. https:\/\/doi.org\/10.1111\/j.1528-1167.2006.00684.x","journal-title":"Epilepsia"},{"key":"12253_CR11","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrneurol.2015.243","volume":"12","author":"AM Kanner","year":"2016","unstructured":"Kanner AM (2016) Management of psychiatric and neurological comorbidities in epilepsy. Nat Rev Neurol 12:106\u2013116. https:\/\/doi.org\/10.1038\/nrneurol.2015.243","journal-title":"Nat Rev Neurol"},{"key":"12253_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1684\/epd.2021.1255","volume":"23","author":"S Balestrini","year":"2021","unstructured":"Balestrini S, Arzimanoglou A, Bl\u00fcmcke I et al (2021) The aetiologies of epilepsy. Epileptic Disord 23:1\u201316. https:\/\/doi.org\/10.1684\/epd.2021.1255","journal-title":"Epileptic Disord"},{"key":"12253_CR13","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40266-021-00837-7","volume":"38","author":"M Galovic","year":"2021","unstructured":"Galovic M, Ferreira-Atuesta C, Abraira L et al (2021) Seizures and Epilepsy After Stroke: Epidemiology, Biomarkers and Management. Drugs Aging 38:285\u2013299. https:\/\/doi.org\/10.1007\/s40266-021-00837-7","journal-title":"Drugs Aging"},{"key":"12253_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s42466-022-00205-9","volume":"4","author":"S Seidel","year":"2022","unstructured":"Seidel S, Wehner T, Miller D, Wellmer J, Schlegel U, Gr\u00f6nheit W (2022) Brain tumor related epilepsy: pathophysiological approaches and rational management of antiseizure medication. Neurol Res Pract 4:45. https:\/\/doi.org\/10.1186\/s42466-022-00205-9","journal-title":"Neurol Res Pract"},{"key":"12253_CR15","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1097\/wco.0000000000000505","volume":"30","author":"LL Zimmermann","year":"2017","unstructured":"Zimmermann LL, Martin RM, Girgis F (2017) Treatment options for posttraumatic epilepsy. Curr Opin Neurol 30:580\u2013586. https:\/\/doi.org\/10.1097\/wco.0000000000000505","journal-title":"Curr Opin Neurol"},{"key":"12253_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.seizure.2015.10.002","volume":"33","author":"BP Lucke-Wold","year":"2015","unstructured":"Lucke-Wold BP, Nguyen L, Turner RC et al (2015) Traumatic brain injury and epilepsy: Underlying mechanisms leading to seizure. Seizure 33:13\u201323. https:\/\/doi.org\/10.1016\/j.seizure.2015.10.002","journal-title":"Seizure"},{"key":"12253_CR17","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2217\/thy.10.57","volume":"7","author":"RM Verellen","year":"2010","unstructured":"Verellen RM, Cavazos JE (2010) Post-traumatic epilepsy: an overview. Therapy 7:527\u2013531. https:\/\/doi.org\/10.2217\/thy.10.57","journal-title":"Therapy"},{"key":"12253_CR18","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s40263-023-01033-4","volume":"37","author":"V Villanueva","year":"2023","unstructured":"Villanueva V, Laloyaux C, D\u2019Souza W et al (2023) Effectiveness and Tolerability of 12-Month Brivaracetam in the Real World: EXPERIENCE, an International Pooled Analysis of Individual Patient Records. CNS Drugs 37:819\u2013835. https:\/\/doi.org\/10.1007\/s40263-023-01033-4","journal-title":"CNS Drugs"},{"key":"12253_CR19","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/epi.13670","volume":"58","author":"RS Fisher","year":"2017","unstructured":"Fisher RS, Cross JH, French JA et al (2017) Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE commission for Classification and Terminology. Epilepsia 58:522\u2013530. https:\/\/doi.org\/10.1111\/epi.13670","journal-title":"Epilepsia"},{"key":"12253_CR20","unstructured":"Therapeutic Goods Administration (2017) Product Information: Briviact. https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-brivaracetam-170307-pi-01.pdf. Accessed 5 Sep 2023"},{"key":"12253_CR21","unstructured":"European Medicines Agency (2023) Briviact\u00ae (brivaracetam) Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/briviact-epar-product-information_en.pdf. Accessed 5 Sep 2023"},{"key":"12253_CR22","unstructured":"US Food and Drug Administration (2023) BRIVIACT\u00ae (brivaracetam) prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/205836s014,205837s011,205838s011lbl.pdf. Accessed 5 Sep 2023"},{"key":"12253_CR23","doi-asserted-by":"publisher","DOI":"10.1080\/02688697.2023.2170326","author":"E Vacher","year":"2023","unstructured":"Vacher E, Rodriguez Ruiz M, Rees JH (2023) Management of brain tumour related epilepsy (BTRE): a narrative review and therapy recommendations. Br J Neurosurg. https:\/\/doi.org\/10.1080\/02688697.2023.2170326","journal-title":"Br J Neurosurg"},{"key":"12253_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2019.106505","volume":"99","author":"EC Foo","year":"2019","unstructured":"Foo EC, Geldard J, Peacey C, Wright E, Eltayeb K, Maguire M (2019) Adjunctive brivaracetam in focal and generalized epilepsies: a single-center open-label prospective study in patients with psychiatric comorbidities and intellectual disability. Epilepsy Behav 99:106505. https:\/\/doi.org\/10.1016\/j.yebeh.2019.106505","journal-title":"Epilepsy Behav"},{"key":"12253_CR25","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/ane.12943","volume":"138","author":"E Andres","year":"2018","unstructured":"Andres E, Kerling F, Hamer H, Winterholler M (2018) Behavioural changes in patients with intellectual disability treated with brivaracetam. Acta Neurol Scand 138:195\u2013202. https:\/\/doi.org\/10.1111\/ane.12943","journal-title":"Acta Neurol Scand"},{"key":"12253_CR26","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/j.1528-1167.2010.02746.x","volume":"52","author":"KJ Meador","year":"2011","unstructured":"Meador KJ, Gevins A, Leese PT, Otoul C, Loring DW (2011) Neurocognitive effects of brivaracetam, levetiracetam, and lorazepam. Epilepsia 52:264\u2013272. https:\/\/doi.org\/10.1111\/j.1528-1167.2010.02746.x","journal-title":"Epilepsia"},{"key":"12253_CR27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.yebeh.2017.04.003","volume":"71","author":"LJ Stephen","year":"2017","unstructured":"Stephen LJ, Wishart A, Brodie MJ (2017) Psychiatric side effects and antiepileptic drugs: Observations from prospective audits. Epilepsy Behav 71:73\u201378. https:\/\/doi.org\/10.1016\/j.yebeh.2017.04.003","journal-title":"Epilepsy Behav"},{"key":"12253_CR28","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s40263-023-01013-8","volume":"37","author":"LM Willems","year":"2023","unstructured":"Willems LM, van der Goten M, von Podewils F et al (2023) Adverse Event Profiles of Antiseizure Medications and the Impact of Coadministration on Drug Tolerability in Adults with Epilepsy. CNS Drugs 37:531\u2013544. https:\/\/doi.org\/10.1007\/s40263-023-01013-8","journal-title":"CNS Drugs"},{"key":"12253_CR29","doi-asserted-by":"publisher","first-page":"418","DOI":"10.12998\/wjcc.v3.i5.418","volume":"3","author":"A Arboix","year":"2015","unstructured":"Arboix A (2015) Cardiovascular risk factors for acute stroke: Risk profiles in the different subtypes of ischemic stroke. World J Clin Cases 3:418\u2013429. https:\/\/doi.org\/10.12998\/wjcc.v3.i5.418","journal-title":"World J Clin Cases"},{"key":"12253_CR30","doi-asserted-by":"publisher","first-page":"616","DOI":"10.11622\/smedj.2019158","volume":"60","author":"SA Chohan","year":"2019","unstructured":"Chohan SA, Venkatesh PK, How CH (2019) Long-term complications of stroke and secondary prevention: an overview for primary care physicians. Singapore Med J 60:616\u2013620. https:\/\/doi.org\/10.11622\/smedj.2019158","journal-title":"Singapore Med J"},{"key":"12253_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/acel.12861","volume":"18","author":"V Atella","year":"2019","unstructured":"Atella V, Piano Mortari A, Kopinska J et al (2019) Trends in age-related disease burden and healthcare utilization. Aging Cell 18:e12861. https:\/\/doi.org\/10.1111\/acel.12861","journal-title":"Aging Cell"},{"key":"12253_CR32","unstructured":"Public Health Agency of Canada (2020) Aging and chronic diseases. A profile of Canadian seniors. https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/diseases-conditions\/aging-chronic-diseases-profile-canadian-seniors-report.html. Accessed 29 Mar 2023"},{"key":"12253_CR33","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1212\/wnl.51.5.1256","volume":"51","author":"F Semah","year":"1998","unstructured":"Semah F, Picot MC, Adam C et al (1998) Is the underlying cause of epilepsy a major prognostic factor for recurrence? Neurology 51:1256\u20131262. https:\/\/doi.org\/10.1212\/wnl.51.5.1256","journal-title":"Neurology"},{"key":"12253_CR34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.seizure.2022.03.007","volume":"97","author":"S Lattanzi","year":"2022","unstructured":"Lattanzi S, Canafoglia L, Canevini MP et al (2022) Brivaracetam as add-on treatment in patients with post-stroke epilepsy: real-world data from the BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST). Seizure 97:37\u201342. https:\/\/doi.org\/10.1016\/j.seizure.2022.03.007","journal-title":"Seizure"},{"key":"12253_CR35","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13046-017-0546-9","volume":"36","author":"A Rizzo","year":"2017","unstructured":"Rizzo A, Donzelli S, Girgenti V et al (2017) In vitro antineoplastic effects of brivaracetam and lacosamide on human glioma cells. J Exp Clin Cancer Res 36:76. https:\/\/doi.org\/10.1186\/s13046-017-0546-9","journal-title":"J Exp Clin Cancer Res"},{"key":"12253_CR36","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3389\/fneur.2020.00813","volume":"11","author":"M Maschio","year":"2020","unstructured":"Maschio M, Maialetti A, Mocellini C et al (2020) Effect of Brivaracetam on Efficacy and Tolerability in Patients with Brain Tumor-Related Epilepsy: A Retrospective Multicenter Study. Front Neurol 11:813. https:\/\/doi.org\/10.3389\/fneur.2020.00813","journal-title":"Front Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12253-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12253-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12253-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T15:09:39Z","timestamp":1716995379000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12253-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,4]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["12253"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12253-z","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,4]]},"assertion":[{"value":"11 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JPS has received research funding from Biogen, Department of Defense, Eisai, GW Pharmaceuticals companies, National Institutes of Health, National Science Foundation, NeuroPace, Serina Therapeutics, Shor Foundation for Epilepsy Research, State of Alabama General Funds, and UCB Pharma; has served as a consultant or advisory board member for Elite Medical Experts, GW Pharmaceuticals, LivaNova, Lundbeck, Medical Association of the State of Alabama, NeuroPace, Serina Therapeutics, SK Life Science, and UCB Pharma; has served as an investigator on GW Research Ltd trials; and is an editorial board member for <i>Epilepsy & Behavior<\/i>, <i>Epilepsy & Behavior Reports<\/i> (editor-in-chief), <i>Folia Medica Copernicana<\/i>, <i>Journal of Epileptology<\/i> (associate editor), and <i>Journal of Medical Science<\/i>. HB, DB, TD, FF, VS, and CL are employees of UCB Pharma. WDS has a salary that is part-funded by The University of Melbourne; he has received travel, investigator-initiated, scientific advisory board, and speaker honoraria from UCB Pharma Australia & Global; investigator-initiated, scientific advisory board, travel, and speaker honoraria from Eisai Australia & Global; advisory board honoraria from LivaNova and Tilray; educational grants from Novartis, Pfizer, and Sanofi-Synth\u00e9labo; educational, travel, and fellowship grants from GSK Neurology Australia; and honoraria from ScieGen Pharmaceuticals; he has an equity interest in the device company Epiminder. EF has received research grants from UCB Pharma. PK has served as a consultant for Abbott, Arvelle Therapeutics, Neurelis, and SK Life Science; has been a consultant, advisory board member, and speaker for Aquestive, Eisai, Sunovion, and UCB Pharma; is a member of the medical advisory board of Stratus and the scientific advisory board of OB Pharma; is the CEO of PrevEp; and has received research support from Department of Defense\/Lundbeck and CURE. MR receives payment from Elsevier as editor-in-chief of <i>Seizure<\/i>; and has received research grants and speaker\u2019s fees from Eisai, LivaNova, and UCB Pharma. FR reports personal fees from Angelini Pharma, Arvelle Therapeutics, Eisai, and GW Pharmaceuticals; personal fees and other from Novartis; personal fees and grants from UCB Pharma; and grants from the Detlev-Wrobel-Fonds for Epilepsy Research Frankfurt, Deutsche Forschungsgemeinschaft, the European Union, and the State of Hessen, outside of the submitted work. JS-P has received grants from Bial and UCB Pharma; and reports personal fees from Bial, Eisai, Esteve, Sanofi, and UCB Pharma, outside of the submitted work; VSI has received speaker honoraria from Bial, Eisai, and UCB Pharma. BJS has received speaker honoraria from Al-Jazeera, Desitin, Eisai, GW Pharmaceuticals, Hikma, Novartis, Sandoz, and UCB Pharma; and has served as a consultant for Arvelle Therapeutics, B. Braun, Bial, Desitin, Eisai, GW Pharmaceuticals, and UCB Pharma. AS reports personal fees and grants from Angelini Pharma, Biocodex, Desitin Arzneimittel, Eisai, GW\/Jazz Pharmaceuticals, Marinus Pharma, Precisis, Takeda, UCB Pharma\/Zogenix, and UNEEG Medical; and is editor-in-chief of <i>Clinical Epileptology<\/i> and section editor of <i>Neurological Research and Practice<\/i>. DF is an independent contractor working for UCB Pharma. VV has served as a consultant or on an advisory board for Angelini Pharma, Bial, Biocodex, Eisai, Jazz Pharmaceuticals, Novartis, SK Life Science, Takeda, UCB Pharma, and Xenon; has received research grants from Bial, Eisai, and UCB Pharma; and has received speaker\u2019s honoraria from Angelini Pharma, Bial, Eisai, Jazz Pharmaceuticals, Novartis, and UCB Pharma. DB, TD, FF and CL have stocks or stock options in UCB Pharma. We confirm that we have read the Journal\u2019s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This research study was conducted retrospectively from data obtained for clinical purposes. The EXPERIENCE database consisted of Health Insurance Portability and Accountability Act\u2013 and General Data Protection Regulation (GDPR)\u2013compliant anonymized data; as such, no ethics committee approval was required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}